These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 35213468)

  • 1. Fibrinolysis Shutdown in Severe COVID-19: Highly Prevalent but not Independently Predictive of Thrombosis or Poorer Outcomes.
    Littlejohn J; Vasovic LV; Cushing MM; Barie PS
    J Am Coll Surg; 2022 Jan; 234(1):97-98. PubMed ID: 35213468
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19?
    Nielsen ND; Rollins-Raval MA; Raval JS; Thachil J
    Thromb Res; 2022 Feb; 210():1-3. PubMed ID: 34953317
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrinolysis Shutdown in COVID-19-Associated Coagulopathy: A Crosstalk among Immunity, Coagulation, and Specialists in Medicine and Surgery.
    Walsh MM; Khan R; Kwaan HC; Neal MD
    J Am Coll Surg; 2021 Jun; 232(6):1003-1006. PubMed ID: 33839011
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibrinolysis Shutdown and Thrombosis in a COVID-19 ICU.
    Creel-Bulos C; Sniecinski R
    Shock; 2021 Jun; 55(6):845-846. PubMed ID: 33989265
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications.
    Meizoso JP; Moore HB; Moore EE
    J Am Coll Surg; 2021 Jun; 232(6):995-1003. PubMed ID: 33766727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombosis and Coagulopathy in COVID-19.
    Gómez-Mesa JE; Galindo-Coral S; Montes MC; Muñoz Martin AJ
    Curr Probl Cardiol; 2021 Mar; 46(3):100742. PubMed ID: 33243440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic Shutdown in COVID-19 Is Likely a Misnomer.
    Lisman T
    Shock; 2021 Jun; 55(6):844-845. PubMed ID: 33989264
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence and Outcomes of Thrombotic Events in Symptomatic Patients With COVID-19.
    Elbadawi A; Elgendy IY; Sahai A; Bhandari R; McCarthy M; Gomes M; Bishop GJ; Bartholomew JR; Kapadia S; Cameron SJ
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):545-547. PubMed ID: 32990453
    [No Abstract]   [Full Text] [Related]  

  • 9. Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration.
    Barral M; Arrive L; El Mouhadi-Barnier S; Cornelis FH
    Intensive Care Med; 2021 Sep; 47(9):1034-1036. PubMed ID: 34132839
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolysis Resistance: A Potential Mechanism Underlying COVID-19 Coagulopathy.
    Weiss E; Roux O; Moyer JD; Paugam-Burtz C; Boudaoud L; Ajzenberg N; Faille D; de Raucourt E
    Thromb Haemost; 2020 Sep; 120(9):1343-1345. PubMed ID: 32645725
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19-associated Coagulopathy.
    Görlinger K; Levy JH
    Anesthesiology; 2021 Mar; 134(3):366-369. PubMed ID: 33417671
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection.
    Wright FL; Vogler TO; Moore EE; Moore HB; Wohlauer MV; Urban S; Nydam TL; Moore PK; McIntyre RC
    J Am Coll Surg; 2020 Aug; 231(2):193-203.e1. PubMed ID: 32422349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic Hemostasis and Fibrinolysis Assays in Intensive Care COVID-19 Patients and Association with Thrombosis and Bleeding-A Systematic Review and a Cohort Study.
    Hvas CL; Larsen JB; Adelborg K; Christensen S; Hvas AM
    Semin Thromb Hemost; 2022 Feb; 48(1):31-54. PubMed ID: 34715692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies.
    Gando S; Wada T
    Front Immunol; 2021; 12():649122. PubMed ID: 34177896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of Thrombotic Events in Coronavirus Disease-19 (COVID-19) Patients and Effect on Outcomes (from a Multicenter Electronic Health Record Database).
    Mukherjee A; Pakhchanian H; Raiker R; Singh S; Chatterjee A
    Am J Cardiol; 2021 May; 147():150-152. PubMed ID: 33689698
    [No Abstract]   [Full Text] [Related]  

  • 16. A new inflammatory-microthrombotic syndrome as an explanation for thrombotic complications in patients with COVID-19.
    Valga F; Vega-Díaz N; Macía M; Rodríguez-Pérez JC
    Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):115-116. PubMed ID: 33069615
    [No Abstract]   [Full Text] [Related]  

  • 17. Fibrinolysis Shutdown in COVID-19-Infected Patients Can Result from Iron-Induced Stabilization of Fibril Clots.
    Sukhomlin T
    J Am Coll Surg; 2020 Nov; 231(5):607-608. PubMed ID: 32972832
    [No Abstract]   [Full Text] [Related]  

  • 18. Alterations in the lipid profile associate with a dysregulated inflammatory, prothrombotic, anti-fibrinolytic state and development of severe acute kidney injury in coronavirus disease 2019 (COVID-19): A study from Cincinnati, USA.
    Henry BM; Szergyuk I; de Oliveira MHS; Abosamak MF; Benoit SW; Benoit JL; Lippi G
    Diabetes Metab Syndr; 2021; 15(3):863-868. PubMed ID: 33878674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolysis Shutdown Is Associated With Thrombotic and Hemorrhagic Complications and Poorer Outcomes After Liver Transplantation.
    Nicolau-Raducu R; Beduschi T; Vianna R; Diez C; Sleem M; Singh BP; Vasileiou G; Raveh Y
    Liver Transpl; 2019 Mar; 25(3):380-387. PubMed ID: 30548128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normal Response to Fibrinolytic Challenge in COVID-19 Patients: Viscoelastic Evaluation Using Urokinase-Modified Thromboelastography.
    Panigada M; Meli A; Properzi P; Grasselli G; Iapichino GE
    J Am Coll Surg; 2021 May; 232(5):803-805. PubMed ID: 33726958
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.